Côlon & Rectum

, Volume 8, Issue 2, pp 75–76

Médecine personnalisée en oncologie digestive : vers de nouveaux horizons

Éditorial / Editorial
  • 199 Downloads

Références

  1. 1.
    Amado RG, Wolf M, Peeters M, et al (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRefGoogle Scholar
  2. 2.
    Bonnes pratiques pour la recherche à visée théranostique de mutations somatiques dans les tumeurs solides. Institut national du cancer. http://www.e-cancer.fr/soins/plates-formes-hospitalieresdegénétiquemoléculaire
  3. 3.
    Van Cutsem E, Köhne CH, Láng I, et al (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRefGoogle Scholar
  4. 4.
    Douillard JY, Oliner KS, Siena SJ, et al (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034PubMedCrossRefGoogle Scholar
  5. 5.
    Schwartzberg LS, Rivera F, Karthaus M, et al (2013). Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 31 (Suppl. abstr 3631)Google Scholar
  6. 6.
    Peeters M, Oliner KS, Parker A, et al (2013). Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19:1902–1912PubMedCrossRefGoogle Scholar
  7. 7.
    Patterson SD, Peeters M, Siena S, et al (2013). Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). J Clin Oncol 31 (Suppl. abstr 3617)Google Scholar
  8. 8.
    Douillard JY, Siena S, Cassidy J, et al (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705PubMedCrossRefGoogle Scholar
  9. 9.
    Bokemeyer C, Van Cutsem E, Rougier P, et al (2012). Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466–1475PubMedCrossRefGoogle Scholar
  10. 10.
    Stintzing S, Jung A, Rossius L, et al (2013). Analysis of KRAS/ NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. Eur J Cancer 49(suppl.3 LBA17)Google Scholar

Copyright information

© Springer-Verlag France 2014

Authors and Affiliations

  1. 1.Service de pathologieInstitut du Cancer de MontpellierMontpellierFrance

Personalised recommendations